Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extended-spectrum beta-lactamases: a clinical update.

David L Paterson1, Robert A Bonomo

  • 1Infectious Disease Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. patersond@dom.pitt.edu

Clinical Microbiology Reviews
|October 15, 2005
PubMed
Summary

Extended-spectrum beta-lactamases (ESBLs) are evolving enzymes conferring antibiotic resistance. Detecting ESBLs is crucial for effective treatment, as resistance limits therapeutic options for bacterial infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis.

Intensive care medicine·2024
Same author

<i>Pseudomonas stutzeri</i> bloodstream infection is a prevailing community-onset disease with important mortality rates: results from a retrospective observational study in Australia.

Infectious diseases (London, England)·2024
Same author

Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis.

Intensive care medicine·2024
Same author

Comparing Polymerase Chain Reaction Testing of Nasopharyngeal Swab and Lower Respiratory Tract Specimens for the Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia.

Open forum infectious diseases·2024
Same author

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials.

Expert opinion on investigational drugs·2024
Same author

Host response signature trends in bacteraemia - authors' response.

Infectious diseases (London, England)·2024

Area of Science:

  • Microbiology
  • Molecular Biology
  • Clinical Medicine

Background:

  • Extended-spectrum beta-lactamases (ESBLs) are enzymes that confer resistance to key antibiotics like cephalosporins.
  • These enzymes often arise from mutations in common beta-lactamase genes (TEM, SHV) or novel lineages.
  • ESBLs are frequently plasmid-mediated and co-exist with resistance genes to other antibiotic classes, complicating treatment.

Purpose of the Study:

  • To review the evolution and clinical significance of ESBLs.
  • To discuss the challenges in detecting and treating infections caused by ESBL-producing bacteria.
  • To highlight the importance of understanding antibiotic resistance mechanisms.

Main Methods:

  • Review of scientific literature on ESBLs.

Related Experiment Videos

  • Analysis of clinical implications and resistance trends.
  • Examination of detection methodologies and treatment strategies.

    • Main Results:

    • ESBLs are a growing threat, limiting treatment options for gram-negative bacterial infections.
    • Carbapenems are the preferred treatment, but carbapenem resistance is emerging.
    • Current detection methods rely on the principle of clavulanic acid potentiating cephalosporin activity.

    Conclusions:

    • ESBLs exemplify bacterial adaptation to antimicrobial pressure.
    • Effective detection and appropriate antibiotic selection are critical for managing ESBL infections.
    • Continued surveillance and research are necessary to combat the rise of antibiotic resistance.